Literature DB >> 21626553

Milestones in atypical and secondary Parkinsonisms.

Gregor K Wenning1, Irene Litvan, Eduardo Tolosa.   

Abstract

During the last decades, atypical parkinsonian disorders such as multiple system atrophy, dementia with Lewy bodies, progressive supranuclear palsy, and corticobasal degeneration along with secondary parkinsonian disorders have been increasingly recognized as important causes of parkinsonism. Although treatment options are largely limited to date, remarkable progress has occurred through advances in the fields of molecular biology and diagnostic neuroimaging, resulting in intense preclinical drug discovery programs. Early-investigation-assisted clinical diagnosis has become more crucial than ever because disease-modifying therapies will hopefully become available within this decade.
Copyright © 2011 Movement Disorder Society.

Entities:  

Mesh:

Year:  2011        PMID: 21626553     DOI: 10.1002/mds.23713

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  25 in total

1.  Reversible progressive supranuclear palsy-like phenotype as an initial manifestation of HIV infection.

Authors:  Wooyoung Jang; Joong-Seok Kim; Jin Young Ahn; Hee-Tae Kim
Journal:  Neurol Sci       Date:  2011-12-09       Impact factor: 3.307

2.  Treatment options for tauopathies.

Authors:  Tarik Karakaya; Fabian Fußer; David Prvulovic; Harald Hampel
Journal:  Curr Treat Options Neurol       Date:  2012-04       Impact factor: 3.598

3.  Co-occurrence of parkinsonism and dementia in clinical practice: relevant differential diagnoses.

Authors:  I Liepelt-Scarfone; M Jamour; W Maetzler
Journal:  Z Gerontol Geriatr       Date:  2012-01       Impact factor: 1.281

4.  Parkinsonian features in hereditary diffuse leukoencephalopathy with spheroids (HDLS) and CSF1R mutations.

Authors:  Christina Sundal; Shinsuke Fujioka; Jay A Van Gerpen; Christian Wider; Alexandra M Nicholson; Matt Baker; Elizabeth A Shuster; Jan Aasly; Salvatore Spina; Bernardino Ghetti; Sigrun Roeber; James Garbern; Alex Tselis; Russell H Swerdlow; Bradley B Miller; Anne Borjesson-Hanson; Ryan J Uitti; Owen A Ross; A Jon Stoessl; Rosa Rademakers; Keith A Josephs; Dennis W Dickson; Daniel Broderick; Zbigniew K Wszolek
Journal:  Parkinsonism Relat Disord       Date:  2013-06-17       Impact factor: 4.891

5.  COGNITIVE DYSFUNCTION IN FMR1 PREMUTATION CARRIERS.

Authors:  Andreea Seritan; Jennifer Cogswell; Jim Grigsby
Journal:  Curr Psychiatry Rev       Date:  2013-02

6.  Speech disorders reflect differing pathophysiology in Parkinson's disease, progressive supranuclear palsy and multiple system atrophy.

Authors:  Jan Rusz; Cecilia Bonnet; Jiří Klempíř; Tereza Tykalová; Eva Baborová; Michal Novotný; Aaron Rulseh; Evžen Růžička
Journal:  J Neurol       Date:  2015-02-17       Impact factor: 4.849

7.  Quality of life in patients with progressive supranuclear palsy: one-year follow-up.

Authors:  Tatjana Pekmezović; Milica Ječmenica-Lukić; Igor Petrović; Vladana Špica; Aleksandra Tomić; Vladimir S Kostić
Journal:  J Neurol       Date:  2015-06-13       Impact factor: 4.849

8.  Neurodegenerative disease: can synucleinopathy and tauopathy be identified during life?

Authors:  Shin-ichiro Kubo; Nobutaka Hattori
Journal:  Nat Rev Neurol       Date:  2013-07-16       Impact factor: 42.937

Review 9.  Clinical trials: past, current, and future for atypical Parkinsonian syndromes.

Authors:  Richard M Tsai; Adam L Boxer
Journal:  Semin Neurol       Date:  2014-06-25       Impact factor: 3.420

10.  Presynaptic dopamine depletion determines the timing of levodopa-induced dyskinesia onset in Parkinson's disease.

Authors:  Han Soo Yoo; Seok Jong Chung; Su Jin Chung; Hyojeong Moon; Jung Su Oh; Jae Seung Kim; Jin Yong Hong; Byoung Seok Ye; Young Ho Sohn; Phil Hyu Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-10-26       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.